Leukemia Study Notes

Exemplar Learning Outcomes

The understanding of leukemia encompasses multiple learning outcomes that include:

Analyze leukemia in the context of cellular regulation, including the mechanisms by which cancer cells evade normal cell cycle controls.
Describe the pathophysiology of leukemia, focusing on how it disrupts normal hematopoiesis and immune function.
Describe the etiology (causes) of leukemia, including genetic, environmental, and viral factors.
Compare the risk factors for and prevention strategies for leukemia, with an emphasis on lifestyle modifications and early detection strategies.
Identify the clinical manifestations (signs and symptoms) of leukemia, noting how these can vary by leukemia type and patient demographics.
Summarize the diagnostic tests and therapies utilized by interprofessional teams for the collaborative care of individuals diagnosed with leukemia, emphasizing the role of genetic testing and targeted therapies.
Differentiate the care considerations for patients with leukemia across various stages of life, focusing on age-specific responses and treatment adaptations.
Apply the nursing process to provide culturally competent care for individuals diagnosed with leukemia, ensuring respect for patient values and beliefs.

Overview of Leukemia

Leukemia is characterized as a chronic malignant disorder affecting white blood cells (WBCs) and their precursors, leading to severe complications and significantly impacting patients' quality of life. It is defined by:

The replacement of normal bone marrow by malignant immature white blood cells (WBCs), disrupting the production of healthy blood cells.
The presence of abnormal immature circulating WBCs in the bloodstream, which impairs immune response and increases susceptibility to infections.
The infiltration of malignant cells into organs such as the liver, spleen, and lymph nodes, resulting in organ dysfunction and other systemic effects.

Pathophysiology and Etiology

Leukemia is classified by several factors, including:

Acuity: Acute and chronic leukemias, where acute leukemia progresses rapidly and is more severe, often requiring immediate attention.
Predominant Cell Type: Lymphocytic and myeloid leukemias, impacting different cellular lineages in the bone marrow.

Most Common Types:

In Children: Acute lymphocytic (lymphoblastic) leukemia, which is the most prevalent form among pediatric cancers.
In Adults: Acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), which present with distinct pathology and treatment requirements.

Acute Myeloid Leukemia (AML)

Characteristics:

Defined by uncontrolled proliferation of myeloblasts, leading to hyperplasia of bone marrow and splenomegaly (enlargement of the spleen).
Average age at diagnosis: 68 years, indicating it is predominantly an illness of older adults with possible prior health conditions.

Clinical Manifestations:

Neutropenia and thrombocytopenia contribute to recurrent severe infections and bleeding tendencies, including:
  - Petechiae (small red or purple spots), purpura, and ecchymoses (bruising due to blood vessel rupture).
  - Epistaxis (nosebleeds) and hematomas arising spontaneously due to low platelet counts.
  - Hematuria (blood in urine) and gastrointestinal (GI) bleeding, which can lead to significant morbidity.
Anemia can manifest as pallor, fatigue, and weakness, often presenting late in the disease course.
Causes of death typically involve infections or hemorrhage, underlining the critical need for proactive management of these complications.

Blood Test Findings:

Complete Blood Count (CBC) may show normocytic, normochromic anemia with elevated blasts, necessitating further diagnostic evaluation to confirm AML.

Chronic Myeloid Leukemia (CML)

Characteristics:

Involves abnormal proliferation of all elements in bone marrow, disrupting normal hematopoiesis. Patients often present with splenomegaly.
Affects men more frequently than women, and the average age at diagnosis is approximately 65 years, often correlating with other comorbidities.
Rare in children, often associated with the presence of the Philadelphia chromosome, which is a gene fusion resulting from a translocation (bcr-abl).
CML may arise from exposure to high doses of ionizing radiation, indicating environmental risk factors.

Phases:

Chronic Phase: Often asymptomatic or presents with vague symptoms; patients may be diagnosed incidentally during routine blood tests.
Accelerated Phase: Symptoms may include decreased appetite, weight loss, fever, and increased leukocyte counts.
Acute (Blast) Phase: Characterized by proliferation of blast cells leading to infiltration in tissues and organs, causing symptoms such as splenomegaly, bone pain, and pronounced fluctuations in platelet counts.

Acute Lymphocytic Leukemia (ALL)

Characteristics:

The most common type of leukemia in children and adolescents, associated with specific genetic factors, including chromosomal abnormalities.
Characterized by rapid onset and proliferation of lymphoblasts in the bone marrow, resulting in significant suppression of normal hematopoiesis and immune function.

Clinical Manifestations:

Symptoms include infections, bleeding, anemia, lymphadenopathy (swollen lymph nodes), and organomegaly (enlargement of liver/spleen).
Patients may also experience bone pain, headaches, visual disturbances, vomiting, and seizures, reflecting widespread systemic involvement.
Elevated WBC counts typically reveal increased lymphocyte levels, indicating a need for intensive management.

Treatment Response:

Combination therapies yield remission in 80-90% of adults, although relapse is common, highlighting the need for individualized treatment plans.
Child survival rates exceed 90%, making early diagnosis and intervention critical in pediatric populations.

Chronic Lymphocytic Leukemia (CLL)

Characteristics:

Features proliferation and accumulation of small, abnormal, mature lymphocytes, representing the most common type of leukemia in adults, often asymptomatic in early stages.
Displays a slow onset with vague symptoms, and patients may not require immediate treatment.

Clinical Manifestations:

Patients may experience anemia, recurrent infections due to immune compromise, and unexplained lymphadenopathy, splenomegaly, and hepatomegaly.
The 5-year survival rate for CLL is approximately 85%, though this can vary based on prognostic factors.

Risk Factors

Key risk factors for leukemia include:

Gender: Men are affected more frequently than women, indicating the need for gender-specific studies and awareness.
Immunodeficiency States: Children with compromised immune conditions face higher risks for leukemia development.
Previous Cancer Treatments: History of chemotherapy or radiation therapy can increase the risk for developing secondary leukemias.
Genetic Disorders: Certain inherited conditions, such as Down syndrome, can predispose individuals to leukemia.
Environmental Factors:
  - Cigarette smoking is a known risk factor linked to various types of leukemia.
  - Exposure to chemicals like benzene has been implicated in the etiology of certain leukemias.
  - High-dose ionizing radiation significantly raises leukemia risk, particularly in survivors of nuclear accidents.
Few known causes are associated with childhood leukemias, necessitating further research into environmental and genetic contributions.

Clinical Manifestations

General manifestations of leukemia can result from:

Anemia: Leading to fatigue, pallor, and weakness, significantly affecting daily activities and overall quality of life.
Infection: Resulting from compromised immunity due to leukocyte dysfunction, making patients susceptible to opportunistic infections.
Bleeding: From thrombocytopenia, which may present as easy bruising or bleeding tendencies.
Other manifestations derived from leukemic infiltration into tissues, increased metabolism, and destruction of leukocytes by the body may complicate diagnosis.

Collaborative Treatment Approaches

The collaborative care of individuals with leukemia focuses on:

Achieving remission or a cure, which is more frequently achieved in children, with ongoing research targeting more effective treatments.
Symptom relief through various therapeutic strategies, including pain management, nutritional support, and psychosocial interventions.

Diagnostic Tests

Essential tests include:

Complete Blood Count (CBC) with differential to assess blood cell counts and morphology.
Platelet count measurement is crucial as it indicates bleeding risk.
Bone marrow examination (aspiration and biopsy) to assess the presence of leukemic cells, with cytogenetic analysis to identify specific mutations or chromosomal abnormalities.

Surgical Options

Bone Marrow Transplant (BMT)

Considered the treatment of choice for specific types of leukemia, often in conjunction with chemotherapy to improve outcomes.
Types of BMT:
- Allogeneic BMT: Uses donor marrow with closely matched tissue type, allowing for healthy hematopoietic stem cells to repopulate the patient's bone marrow.
- Autologous BMT: Utilizes the patient’s own bone marrow, which must be harvested, treated, and reinfused after high-dose chemotherapy.

Stem Cell Transplant (SCT)

Serves as an alternative to BMT, providing complete blood cell line replacement with donor cells, which can offer improved outcomes for patients with certain leukemia types.
Donor stem cells need to closely match the recipient's tissue type, and hematopoietic growth factors may be administered to enhance stem cell yields in blood.

Graft-versus-host disease (GVHD)

A complication associated with allogeneic BMT or SCT where donor immune cells perceive recipient tissues as foreign:
- Acute GVHD: May develop within days to six months post-transplant, with varying severity impacting organ function.
- Chronic GVHD: Develops three months or more after the transplant, potentially causing long-term complications in multiple organs.

Pharmacologic Therapy

Chemotherapy

Can involve single-agent or combination therapies, aimed at reducing drug resistance and toxicity while disrupting cell growth at various stages (induction, consolidation, and maintenance phases).
Treatment involves two principal phases: induction and post-remission, with close monitoring for side effects and complications such as tumor lysis syndrome (TLS).

Biological Therapy

Utilizes the body’s natural substances, such as cytokines (e.g., interferons and interleukins), to modify responses to cancer cells and enhance immunity.
Colony-stimulating factors may also be used to address bone marrow suppression following aggressive chemotherapy regimens.

Radiation Therapy

Acts by damaging cellular DNA, hindering replication, with rapid responses noted in cells that divide quickly (like cancer cells). Careful consideration is taken to minimize impact on normal regenerative cells that can recover.

Lifespan Considerations

Children

Majority of cases are ALL, with the remaining usually being AML. Early diagnosis is critical in this demographic.
No established screening tests; symptoms typically relate to decreased red and white blood cells leading to anemia and infection.
Prognosis can often be assessed by age at diagnosis and initial white blood cell count. Chemotherapy is predominantly the main treatment modality, with 5-year survival rates for ALL exceeding 91% and AML at approximately 66%.
Children successfully treated for leukemia face potential health complications in adulthood that require ongoing monitoring and management.

Pregnant Women

Acute leukemia is the most common hematologic cancer during pregnancy, albeit rare, leading to complex management dilemmas.
Treatment poses challenges due to teratogenic effects of chemotherapy and targeted therapies on the fetus, balanced against the mother’s health risks by delaying treatment until postpartum.

Older Adults

CLL primarily occurs in older adults, where comorbidities influence prognosis and treatment decisions considerably.
AML requires a highly individualized approach, with treatment often deferred unless patients exhibit symptomatic presentations due to advanced age and overall health considerations.

Nursing Process

Assessment

Patient Observation and Interview

Symptoms to look out for:
  - Pale or visibly bruised skin indicative of hematologic disorders.
  - Fatigue, weakness, and dyspnea on exertion, relating to anemia.
  - Frequent infections and sore throat, common manifestations of leukopenia.
  - Night sweats, bleeding gums or nosebleeds, and unexplained weight loss, which may signal advanced disease.
  - History of exposure to ionizing radiation or potential chemical risks, alongside previous cancer treatments, guiding risk stratification.
  - Evidence of immune disorders in patient history should be documented for comprehensive care.

Physical Examination

Identification of crucial physical signs:
  - Bruising, purpura, petechiae, or mouth ulcers/lesions indicating hematologic dysfunction.
  - Overall paleness and monitoring vital signs, including orthostatic measurements to evaluate fluid status.
  - Assessment of heart and lung sounds, alongside abdominal examination to detect organomegaly.
  - Stool tests for occult blood may also be warranted based on presenting symptoms.

Diagnosis

Clinical diagnoses may include:

Increased potential for infection due to immature or abnormal leukocytes leading to poor immune responses.
Risk of bleeding complications related to decreased platelet counts and clotting capacity.
Significant weight loss impacting nutritional status and overall health.
Increased susceptibility of oral membranes leading to infection risks, often requiring oral care interventions.
Anticipated side effects from medications administered warranting preemptive management.
Managing emotional responses through effective coping strategies and mental health support.
Fatigue stemming from anemia necessitating energy conservation techniques.
Altered tissue perfusion due to anemic conditions affecting oxygen delivery.
Levels of anxiety and fear related to diagnosis and treatment ramifications deserving supportive counseling.

Planning

Goals for care may include ensuring the patient:

Can articulate strategies for reducing infection risks, empowering self-management.
Demonstrates no signs or symptoms of infection throughout the treatment course, indicating effective management.
Achieves appropriate developmental milestones post-treatment, especially in pediatric populations.
Has the opportunity to express emotions surrounding their diagnosis, promoting mental well-being.
Receives adequate nutritional intake to support growth/weight maintenance, including dietary consultations.
Can report symptoms of potential complications to the care team promptly, facilitating timely interventions.

Implementation

Multidisciplinary Treatment Role

Nurses play crucial roles in ongoing psychosocial assessments, alongside providing emotional support to patients and families.
The type of leukemia being treated influences treatment settings, such as in-hospital versus outpatient care, reflecting care complexity.
Utilize hospital time to coordinate family coping strategies, nutrition, sleep, medication adherence, and securing support systems to enhance recovery outcomes.

Medication Impact Management

Monitor patient weight daily and evaluate infusion sites regularly to assess for adverse reactions, adjusting care plans accordingly.
Track patient output and monitor renal function, particularly with nephrotoxic medications like cyclophosphamide and others, impacting treatment safety.
Administer assigned medications as ordered by the physician, ensuring adherence to protocols and patient safety.

Infection Prevention

Given that infections remain a significant cause of mortality in patients with leukemia:
  - Mucous membranes are particularly fragile, necessitating careful oral care.
  - Changes in leukocyte function weaken immune and inflammatory responses, requiring vigilant monitoring for infection signs.
  - Therapy such as chemotherapy and radiation exacerbates bone marrow suppression; hence, implement protective isolation as necessary.
  - Timely administration of prophylactic antibiotics should be prioritized.

Bleeding Risk Protection

Because bleeding represents the second most common cause of death:
  - Instruct patients to avoid activities that can increase bleeding risks, including forceful actions like blowing the nose or straining.
  - Vigilantly monitor for abnormal lab results in blood electrolyte levels and signs of tumor lysis syndrome (TLS), facilitating early intervention.
  - Conduct regular vital sign checks at every four-hour interval and assess body systems for any signs of bleeding each shift, ensuring timely responses if complications arise.
  - Limit invasive procedures as necessary, and apply appropriate pressure to injection sites post-draws for sufficient bleeding control.

Evaluation

Expected patient outcomes post-treatment would include:

Absence of infection signs throughout the treatment period, indicating strong immune function restoration.
Maintenance of a urinary output of at least 0.5 extmL/kg/hr0.5extmL/kg/hr as a marker of adequate kidney function and hydration status.
Correct levels of hydration maintained through appropriate fluid management protocols.
Electrolyte balance within normal limits to prevent complications associated with imbalances.
Patient reports pain on an acceptable scale, emphasizing the effectiveness of pain management strategies.
Patients demonstrate adequate knowledge about the disease, proposed treatment regimens, and overall well-being, allowing for satisfactory quality of life enhancement.

Conclusion

Understanding leukemia, its etiology, pathophysiology, clinical manifestations, treatment options, and strategies for nursing care enables healthcare providers to manage the disease effectively and compassionately, maintaining the quality of life for affected individuals across different life stages. Continuous education, research, and improvement of treatment standards are vital for enhancing patient outcomes and quality of care in leukemia management.